Research programme: synthetic macrocycles - Ensemble Therapeutics/Bristol-Myers Squibb

Drug Profile

Research programme: synthetic macrocycles - Ensemble Therapeutics/Bristol-Myers Squibb

Latest Information Update: 09 Jan 2012

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; Ensemble Discovery
  • Developer Bristol-Myers Squibb; Ensemble Therapeutics
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 05 Jan 2012 Alliance between Ensemble Therapeutics and Bristol-Myers Squibb extended
  • 22 Jun 2010 Ensemble Discovery is now called Ensemble Therapeutics
  • 16 Apr 2009 Early research in Undefined indication in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top